For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues. Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich has announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyse an ambitious future phase to… Read More
Scientists at the Wellcome Sanger Institute in collaboration with Pacific Biosciences (PacBio) have launched a new initiative to map how gene activity shapes the immune system. It is hoped that the project will identify new therapeutic targets for conditions such as inflammatory bowel disease (IBD). … Read More
New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More
UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More
New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. The team from the Wellcome Sanger Institute, the University of Oxford, and collaborators built on their previous work that identified different subgroups of… Read More
UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More
Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. Read More
A new method of separating cancer cells from non-cancer cells has been developed by researchers at the Wellcome Sanger Institute, in a boost for those working to better understand cancer biology using single-cell mRNA sequencing. The study, published in Communications Biology, improves on existing methods to identify… Read More
Animals with a large difference in lifespan and size end their natural lives with a similar number of genetic changes, researchers have discovered. The findings come from a study by the Wellcome Sanger Institute which analysed genomes from 16 species of mammal to understand the role genetic… Read More
